Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$29.99 -0.9%	$30.15	$23.12 ▼ $36.45	$4.95B	0.44	1.73 million shs	539,875 shs
ALXO ALX Oncology	$0.47 -2.4%	$0.48	$0.40 ▼ $8.78	$25.15M	1.11	914,919 shs	174,400 shs
FGEN FibroGen	$7.38 +3.1%	$6.97	$4.50 ▼ $38.25	$29.80M	0.74	75,875 shs	11,341 shs
PCRX Pacira BioSciences	$22.61 -1.3%	$24.81	$11.16 ▼ $27.64	$1.05B	0.48	898,910 shs	181,624 shs
VIE Viela Bio	$53.01	$53.01	$25.02 ▼ $65.00	$2.91B	0.43	1.07 million shs	N/A

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	+5.32%	+1.51%	+9.95%	+28.47%
ALXO ALX Oncology	0.00%	+2.66%	-5.84%	-3.75%	-93.17%
FGEN FibroGen	0.00%	+25.66%	+8.37%	-4.63%	-72.50%
PCRX Pacira BioSciences	0.00%	-1.31%	-5.53%	-8.29%	+5.24%
VIE Viela Bio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALKS Alkermes	4.8064 of 5 stars	4.4	1.0	0.0	4.2	3.0	2.5	1.9
ALXO ALX Oncology	3.584 of 5 stars	3.4	3.0	0.0	0.0	2.4	4.2	1.3
FGEN FibroGen	4.7284 of 5 stars	3.3	4.0	0.0	4.7	3.8	3.3	0.6
PCRX Pacira BioSciences	3.1147 of 5 stars	2.2	1.0	0.0	3.9	2.1	2.5	0.6
VIE Viela Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.83	Moderate Buy	$40.00	33.36% Upside
ALXO ALX Oncology	2.71	Moderate Buy	$3.30	600.64% Upside
FGEN FibroGen	2.50	Moderate Buy	$250.00	3,289.83% Upside
PCRX Pacira BioSciences	2.33	Hold	$26.44	16.95% Upside
VIE Viela Bio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PCRX, VIE, ALKS, ALXO, and FGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	ALKS Alkermes	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$33.00 ➝ $42.00
5/28/2025	ALKS Alkermes	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral ➝ Buy	$45.00
5/21/2025	ALXO ALX Oncology	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1.20 ➝ $1.00
5/13/2025	ALKS Alkermes	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	FGEN FibroGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$250.00 ➝ $250.00
5/9/2025	ALXO ALX Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00
5/9/2025	PCRX Pacira BioSciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $30.00
5/2/2025	ALKS Alkermes	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/2/2025	ALKS Alkermes	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$39.00 ➝ $40.00
5/2/2025	ALKS Alkermes	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$38.00 ➝ $41.00
4/28/2025	ALKS Alkermes	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underperform ➝ Underperform

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.51B	3.27	$2.63 per share	11.42	$9.05 per share	3.31
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$2.14 per share	N/A
FGEN FibroGen	$29.62M	1.01	N/A	N/A	($50.89) per share	-0.14
PCRX Pacira BioSciences	$700.97M	1.49	$4.27 per share	5.30	$16.86 per share	1.34
VIE Viela Bio	$50M	58.26	N/A	N/A	$7.14 per share	7.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$367.07M	$2.09	14.35	21.89	1.88	23.30%	27.52%	17.98%	7/23/2025 (Estimated)
ALXO ALX Oncology	-$134.85M	-$2.47	N/A	N/A	N/A	N/A	-104.43%	-77.74%	8/14/2025 (Estimated)
FGEN FibroGen	-$47.58M	-$2.50	N/A	N/A	N/A	-9.73%	N/A	-24.77%	8/5/2025 (Estimated)
PCRX Pacira BioSciences	-$99.56M	-$2.28	N/A	8.80	N/A	-14.78%	13.78%	7.00%	7/29/2025 (Estimated)
VIE Viela Bio	-$86.43M	-$7.02	N/A	N/A	N/A	N/A	-33.97%	-31.49%	N/A

Latest PCRX, VIE, ALKS, ALXO, and FGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	FGEN FibroGen	-$0.09	N/A	N/A	N/A	$2.88 million	N/A
7/29/2025	Q2 2025	PCRX Pacira BioSciences	$0.73	N/A	N/A	N/A	$183.11 million	N/A
7/23/2025	Q2 2025	ALKS Alkermes	$0.42	N/A	N/A	N/A	$343.20 million	N/A
5/12/2025	Q1 2025	FGEN FibroGen	$0.75	-$4.00	-$4.75	$0.05	$2.00 million	$2.70 million
5/8/2025	Q1 2025	ALXO ALX Oncology	-$0.47	-$0.58	-$0.11	-$0.58	N/A	N/A
5/1/2025	Q1 2025	ALKS Alkermes	$0.32	$0.13	-$0.19	$0.13	$307.53 million	$306.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
PCRX Pacira BioSciences	N/A	N/A	N/A	N/A	N/A
VIE Viela Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	N/A	3.33	2.92
ALXO ALX Oncology	0.09	5.47	5.47
FGEN FibroGen	N/A	2.02	1.98
PCRX Pacira BioSciences	0.48	2.41	1.99
VIE Viela Bio	N/A	19.51	19.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
ALXO ALX Oncology	97.97%
FGEN FibroGen	72.71%
PCRX Pacira BioSciences	99.73%
VIE Viela Bio	46.98%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.40%
ALXO ALX Oncology	21.00%
FGEN FibroGen	1.98%
PCRX Pacira BioSciences	6.40%
VIE Viela Bio	31.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	1,800	164.90 million	157.65 million	Optionable
ALXO ALX Oncology	40	53.40 million	42.18 million	Optionable
FGEN FibroGen	570	4.04 million	3.96 million	Optionable
PCRX Pacira BioSciences	720	46.29 million	43.33 million	Optionable
VIE Viela Bio	166	54.95 million	N/A	Not Optionable

PCRX, VIE, ALKS, ALXO, and FGEN Headlines

Recent News About These Companies

BETDAQ app download

December 30, 2024 | bwsmartcities.businessworld.inB

dc vs punjab 2022

December 30, 2024 | everythingexperiential.businessworld.inE

Khelo India Khelo lucky 3 result today

December 30, 2024 | bweducation.businessworld.inB

777 Win Sooter

December 30, 2024 | bwdisrupt.businessworld.inB

Therapeutic Drug Monitoring in Rheumatology Has Potential but Faces a Host of Hurdles

October 23, 2024 | medscape.comM

Anti-CD19 Monoclonal Antibody Shows Positive Results in Myasthenia Gravis

October 16, 2024 | msn.com

Dmitry Bivol: Biography, record, fights and more

October 10, 2024 | espn.com

RGNX-Aktie erreicht 52-Wochen-Tief bei 9,28 US-Dollar

October 9, 2024 | de.investing.com

Roche takes on Alexion as FDA approves satralizumab in NMOSD

September 29, 2024 | pharmaphorum.comP

REGENXBIO Inc.: REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

September 17, 2024 | finanznachrichten.de

REGENXBIO ernennt Mitchell Chan zum neuen CFO in Wachstumsphase

September 17, 2024 | de.investing.com

Regenxbio Names Mitchell Chan CFO

September 17, 2024 | markets.businessinsider.com

AstraZeneca spins out biotech to focus on autoimmune candidates

August 27, 2024 | pharmaphorum.comP

Complement Inhibitors Market is Predicted to Exhibit Remarkable Growth During the Study Period (2020-2034) | DelveInsight

August 21, 2024 | prnewswire.co.ukP

Minority Stockholder Was Not a Controller Because Plaintiff Did Not Adequately Plead Actual Control of the Company’s Business Affairs

August 21, 2024 | law.comL

Factor D Complement Inhibitor Market Will Witness Robust Growth with Emerging Therapies by 2034 | DelveInsight

August 19, 2024 | finance.yahoo.com

Litigation Leaders: Adam Siegel of Freshfields on Four ‘Cs’ of the Firm’s Litigation Practice

August 19, 2024 | law.comL

2024 Fire Awards: Meet this year's Ablaze honorees

August 16, 2024 | bizjournals.com

Amgen Touts Q2 Growth Bolstered by Horizon Buy, Promising Obesity Pipeline

August 8, 2024 | biospace.comB

Novel Drug Made of Gold Nanocrystals Appears Safe in Multiple Sclerosis

April 22, 2024 | medpagetoday.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

China Market Movers: MCHI, PDD, BIDU Show Bullish Trends
By Gabriel Osorio-Mazilli | June 16, 2025
View China Market Movers: MCHI, PDD, BIDU Show Bullish Trends
Palantir Defies Bears, Leads S&P 500 in 2025
By Chris Markoch | June 16, 2025
View Palantir Defies Bears, Leads S&P 500 in 2025
Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
By Leo Miller | June 25, 2025
View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
Tariff Talks Advance, What Taiwan Semiconductor Can Deliver
By Gabriel Osorio-Mazilli | June 16, 2025
View Tariff Talks Advance, What Taiwan Semiconductor Can Deliver
MarketBeat Week in Review – 06/16 - 06/20
By MarketBeat Staff | June 21, 2025
View MarketBeat Week in Review – 06/16 - 06/20

PCRX, VIE, ALKS, ALXO, and FGEN Company Descriptions

Alkermes NASDAQ:ALKS

$29.99 -0.29 (-0.95%)

As of 12:17 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

ALX Oncology NASDAQ:ALXO

$0.47 -0.01 (-2.38%)

As of 12:16 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

FibroGen NASDAQ:FGEN

$7.38 +0.23 (+3.15%)

As of 12:15 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Pacira BioSciences NASDAQ:PCRX

$22.61 -0.29 (-1.26%)

As of 12:17 PM Eastern

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Viela Bio NASDAQ:VIE

Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjÃ¶gren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time